Last reviewed · How we verify
Intravenous Vancomycin
At a glance
| Generic name | Intravenous Vancomycin |
|---|---|
| Sponsor | Başakşehir Çam & Sakura City Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis (NA)
- IO Vancomycin Spine (PHASE2, PHASE3)
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis (PHASE3)
- Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers (PHASE2)
- A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients (PHASE4)
- Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia (NA)
- Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Vancomycin CI brief — competitive landscape report
- Intravenous Vancomycin updates RSS · CI watch RSS
- Başakşehir Çam & Sakura City Hospital portfolio CI